Michael B. Harlin

Partner at Neal Gerber Eisenberg, specializing in life sciences intellectual property.

Articles by Michael B. Harlin

Intellectual Property Considerations for Drug Discovery Via Artificial Intelligence

ByMichael B. Harlin

July 26th 2022

Latest Updated Articles

Trending on PharmExec

Novo Nordisk Rebranding to'Novo'

How Doctors Can Be Better Educated About Cortisol Issues

How Cortisol-Targeted Approaches Might be Paired with GLP-1 Medications

The Agentic AI Revolution in Biopharma

Cellectis Transforming Into In Vivo Gene Editing Company